BlackRock Health Sciences Term Trust

BlackRock Health Sciences Term Trust

BlackRock launched the Health Sciences Term Trust in 2005 as a closed-end fund with a fixed termination date, giving portfolio manager Bob Shearer a vehicle designed to hold concentrated, less-liquid positions in healthcare without facing daily redemptions. The fund's original structure called for liquidation around 2015, but shareholders voted to extend it, recognizing the advantage of permanent capital in a sector where clinical catalysts can take years to play out. Shearer and his team operate within BlackRock Fundamental Equity, drawing on the firm's massive healthcare research apparatus but making concentrated bets from a pool of roughly $200–$300 million in net assets. The trust allocates across biopharmaceuticals, medical devices, diagnostics, and healthcare services, with a bias toward companies approaching regulatory milestones or commercial inflection points. Unlike open-end health-sector mutual funds that must maintain liquidity, the trust can hold private companies and founder-led biotechs where lockups matter. Public filings have shown positions in names like Exact Sciences, Intuitive Surgical, and Shire Pharmaceuticals during their respective growth phases. Shearer has said the trust can also invest up to 30% in private companies, a flexibility that brings it closer to a crossover fund than a traditional mutual fund. As of mid-2024, the trust operated with roughly $240 million in net assets and maintained a modest expense ratio below 1.0%. The team size is small relative to the asset base, consistent with BlackRock's model of concentrated, high-conviction portfolios. In early 2024, the trust's board announced another extension of the term structure, confirming that shareholders again preferred the permanent-capital format over a liquidation. The trust sits alongside other BlackRock closed-end funds like the Science and Technology Trust, sharing operational infrastructure but maintaining an independent investment mandate. What separates this vehicle from a standard healthcare ETF or open-end fund is the term structure itself. By locking capital in place, Shearer can take positions that a daily-liquid fund would avoid — pre-IPO biotechs, control-stake collaborations, or companies with binary clinical events where forced selling would crater returns. It is a public-market vehicle engineered to behave like a private fund, a structure that remains rare among large asset managers.